Brain-imaging study finds distinct patterns associated with aging and Alzheimer’s

A study published October 1 in Nature Neuroscience reports that normal aging and Alzheimer’s disease are associated with different patterns of communication across the brain. The findings offer researchers a way to investigate disease-related changes separately from those accompanying age, a distinction that matters for understanding threats to cognitive healthspan.

Lund University’s October 2 research summary highlights a particularly relevant observation: the disease-associated pattern appeared in some people with low levels of Alzheimer’s pathology who had no evident cognitive impairment. That makes the finding interesting for early-detection research, while leaving its usefulness for individual patients unresolved.

What the researchers measured

The observational study analyzed resting-state functional MRI from 973 BioFINDER-2 participants and replicated findings in 129 participants from the Alzheimer’s Disease Neuroimaging Initiative. Researchers combined imaging with amyloid and tau biomarkers and cognitive assessments; analyses also included changes within participants over time.

The main imaging measure described how similar each brain region’s connectivity profile was to other regions. Researchers examined how those measurements aligned with broad organizational axes across the cortex.

Alzheimer’s pathology was associated with changes along an axis linking sensory regions and higher-order association areas. Age-related changes instead aligned with an axis separating representational and executive systems. These were research associations, rather than endpoints demonstrating better memory, preserved independence or treatment benefit.

Why the distinction matters

As the university explains, aging and Alzheimer’s pathology often coexist. Their effects on communication nevertheless appeared as different coordinated patterns across multiple regions. In the disease-associated pattern, higher-order regions became more similar in their communication profiles, while sensory and motor regions became more distinct.

One possible research application is monitoring how brain function responds to an intervention. The university also discusses potential therapeutic investigation, but frames that prospect conditionally: researchers first need to understand the consequences of the observed patterns. A measurable difference does not, by itself, identify something that treatment should reverse.

Where this fits among dementia biomarkers

The National Institute on Aging describes biomarkers as measurable indicators of biological processes. They can help researchers identify suitable trial participants, study early disease changes and track responses to experimental interventions. Clinical interpretation requires a broader assessment rather than reliance on an isolated measurement.

Different imaging methods answer different questions. Structural scans can reveal shrinkage or other damage, while PET imaging can assess molecules such as amyloid or tau. Functional imaging examines another aspect of brain biology: relationships among activity in different areas. Bringing these kinds of information together can help researchers investigate how molecular disease and brain function relate.

That distinction also explains why an early signal is not automatically a useful screening tool. The NIA notes that people can have amyloid deposits without developing Alzheimer’s symptoms. Detecting a biological feature and predicting a person’s future difficulties are separate challenges.

What remains uncertain

The study cannot establish causation. Its whole-brain approach also makes it harder to identify the specific connections driving the patterns. Limited cohort diversity restricts generalizability: more than 90% of BioFINDER participants were native Swedish speakers, and more than 90% of ADNI participants identified as white.

For clinical translation, the important questions include whether the measurements add useful information to existing assessments and whether acting on them improves outcomes. Those questions require further testing. For now, the practical contribution is a framework for studying cognitive vulnerability, with no demonstrated basis for changing an individual’s diagnosis or treatment.